Benjamin Besse, MD, PhD, on EGFR-Mutated NSCLC: Update on Patritumab Deruxtecan in Previously Treated Disease

November 15, 2023 By The ASCO Post Staff

Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Centre, discusses phase II findings from the HERTHENA-Lung01 study, which showed patients with previously treated EGFR-mutated non–small cell lung cancer may benefit from the antibody-drug conjugate patritumab deruxtecan after EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy (Abstract OA05.03). The phase III HERTHENA-Lung02 trial is ongoing.

Related Content